Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.57 |
| ▸ | CCR3 | P51677 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714695 | 0.92 | MCHR1 (0.57) | MCHR1CCR3KDM4EALDH1A1HPGD | |
| SCHEMBL6711315 | 0.92 | CCR3 (0.62) | MCHR1CCR3 | |
| SCHEMBL6714325 | 0.90 | MCHR1 (0.57) | MCHR1CCR3DRD4 | |
| SCHEMBL6719419 | 0.84 | CCR3 (0.51) | CCR3DRD4SSTR5 | |
| SCHEMBL6718721 | 0.83 | MCHR1 (0.58) | MCHR1CCR3DRD4 | |
| SCHEMBL6718424 | 0.81 | CCR3 (0.62) | MCHR1CCR3DRD4 | |
| Hydrochloric Acid SCHEMBL6711564 | 0.80 | CCR3 (0.61) | MCHR1CCR3DRD4 | |
| SCHEMBL6713973 | 0.80 | CCR3 (0.74) | MCHR1CCR3 | |
| SCHEMBL6715786 | 0.80 | CCR3 (0.62) | CCR3DRD4 | |
| SCHEMBL6714466 | 0.80 | DRD4 (0.58) | MCHR1CCR3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | LIPC, CETP, MTTP | MCHR1 2748/4885CCR3 2275/4885KDM4E 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.